A detailed history of Raymond James Financial Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 377,294 shares of ALNY stock, worth $169 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
377,294
Previous 270,450 39.51%
Holding current value
$169 Million
Previous $88.2 Million 95.08%
% of portfolio
0.06%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$311.12 - $482.13 $33.2 Million - $51.5 Million
106,844 Added 39.51%
377,294 $172 Million
Q2 2025

Aug 14, 2025

BUY
$224.32 - $326.09 $331,993 - $482,613
1,480 Added 0.55%
270,450 $88.2 Million
Q1 2025

May 13, 2025

SELL
$233.07 - $290.7 $1.98 Million - $2.48 Million
-8,516 Reduced 3.07%
268,970 $72.6 Million
Q4 2024

Feb 06, 2025

BUY
$232.27 - $300.43 $64.5 Million - $83.4 Million
277,486 New
277,486 $65.3 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $55.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.